Roche Holding AG Cash Flow Conversion Efficiency
Roche Holding AG cash flow conversion efficiency. Based on the latest financial reports, Roche Holding AG (ROG) has a cash flow conversion efficiency ratio of 0.296x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF11.23 Billion ≈ $14.20 Billion USD) by net assets (CHF37.88 Billion ≈ $47.89 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Roche Holding AG (1998–2025)
Cash flow conversion efficiency of Roche Holding AG from 1998 to 2025. This chart illustrates how Roche Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ROG stock price and chart for real-time trading data and today's change.
Roche Holding AG Cash Flow Conversion Ratio Explained
Roche Holding AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Roche Holding AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Roche Holding AG ranked by their cash flow conversion efficiency. Also see market value of Roche Holding AG for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Goldman Sachs Group Inc
NYSE:GS
|
0.050x |
|
Netflix Inc
NASDAQ:NFLX
|
0.079x |
|
Palo Alto Networks Inc
NASDAQ:PANW
|
0.049x |
|
Kweichow Moutai Co Ltd
SHG:600519
|
0.095x |
|
Toyota Motor Corporation ADR
NYSE:TM
|
0.021x |
|
AstraZeneca PLC
F:ZEGA
|
0.112x |
|
Wells Fargo & Company
NYSE:WFC
|
0.051x |
|
Roche Holding AG
SW:ROP
|
0.296x |
Annual Cash Flow Conversion Efficiency for Roche Holding AG (1998–2025)
The table below shows the annual cash flow conversion efficiency of Roche Holding AG from 1998 to 2025. Review Roche Holding AG free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF37.88 Billion ≈ $47.89 Billion |
CHF17.83 Billion ≈ $22.54 Billion |
0.471x | -15.29% |
| 2024-12-31 | CHF36.16 Billion ≈ $45.72 Billion |
CHF20.09 Billion ≈ $25.40 Billion |
0.556x | +14.84% |
| 2023-12-31 | CHF33.26 Billion ≈ $42.05 Billion |
CHF16.09 Billion ≈ $20.35 Billion |
0.484x | -13.41% |
| 2022-12-31 | CHF32.02 Billion ≈ $40.48 Billion |
CHF17.89 Billion ≈ $22.62 Billion |
0.559x | -22.99% |
| 2021-12-31 | CHF28.34 Billion ≈ $35.84 Billion |
CHF20.57 Billion ≈ $26.00 Billion |
0.726x | +58.93% |
| 2020-12-31 | CHF39.77 Billion ≈ $50.28 Billion |
CHF18.16 Billion ≈ $22.96 Billion |
0.457x | -26.84% |
| 2019-12-31 | CHF35.87 Billion ≈ $45.35 Billion |
CHF22.39 Billion ≈ $28.30 Billion |
0.624x | -5.14% |
| 2018-12-31 | CHF30.37 Billion ≈ $38.39 Billion |
CHF19.98 Billion ≈ $25.26 Billion |
0.658x | +5.89% |
| 2017-12-31 | CHF29.01 Billion ≈ $36.67 Billion |
CHF18.02 Billion ≈ $22.79 Billion |
0.621x | +9.36% |
| 2016-12-31 | CHF26.40 Billion ≈ $33.38 Billion |
CHF15.00 Billion ≈ $18.97 Billion |
0.568x | -13.20% |
| 2015-12-31 | CHF23.30 Billion ≈ $29.46 Billion |
CHF15.25 Billion ≈ $19.28 Billion |
0.655x | -11.42% |
| 2014-12-31 | CHF21.56 Billion ≈ $27.26 Billion |
CHF15.93 Billion ≈ $20.14 Billion |
0.739x | -0.48% |
| 2013-12-31 | CHF21.24 Billion ≈ $26.85 Billion |
CHF15.77 Billion ≈ $19.94 Billion |
0.743x | -17.22% |
| 2012-12-31 | CHF16.73 Billion ≈ $21.15 Billion |
CHF15.01 Billion ≈ $18.97 Billion |
0.897x | +0.28% |
| 2011-12-31 | CHF14.48 Billion ≈ $18.31 Billion |
CHF12.95 Billion ≈ $16.38 Billion |
0.894x | -27.27% |
| 2010-12-31 | CHF11.66 Billion ≈ $14.74 Billion |
CHF14.34 Billion ≈ $18.13 Billion |
1.230x | -31.40% |
| 2009-12-31 | CHF9.41 Billion ≈ $11.90 Billion |
CHF16.88 Billion ≈ $21.34 Billion |
1.793x | +692.39% |
| 2008-12-31 | CHF53.82 Billion ≈ $68.05 Billion |
CHF12.18 Billion ≈ $15.40 Billion |
0.226x | +2.83% |
| 2007-12-31 | CHF53.31 Billion ≈ $67.39 Billion |
CHF11.73 Billion ≈ $14.83 Billion |
0.220x | -0.29% |
| 2006-12-31 | CHF46.81 Billion ≈ $59.19 Billion |
CHF10.33 Billion ≈ $13.06 Billion |
0.221x | -7.67% |
| 2005-12-31 | CHF41.74 Billion ≈ $52.77 Billion |
CHF9.97 Billion ≈ $12.61 Billion |
0.239x | +8.46% |
| 2004-12-31 | CHF33.29 Billion ≈ $42.09 Billion |
CHF7.33 Billion ≈ $9.27 Billion |
0.220x | -11.41% |
| 2003-12-31 | CHF29.16 Billion ≈ $36.87 Billion |
CHF7.25 Billion ≈ $9.17 Billion |
0.249x | +552.72% |
| 2002-12-31 | CHF25.77 Billion ≈ $32.58 Billion |
CHF982.00 Million ≈ $1.24 Billion |
0.038x | -74.64% |
| 2001-12-31 | CHF33.87 Billion ≈ $42.82 Billion |
CHF5.09 Billion ≈ $6.43 Billion |
0.150x | +22.90% |
| 2000-12-31 | CHF32.04 Billion ≈ $40.50 Billion |
CHF3.92 Billion ≈ $4.95 Billion |
0.122x | +112.35% |
| 1999-12-31 | CHF30.00 Billion ≈ $37.93 Billion |
CHF1.73 Billion ≈ $2.18 Billion |
0.058x | -63.69% |
| 1998-12-31 | CHF22.82 Billion ≈ $28.84 Billion |
CHF3.62 Billion ≈ $4.57 Billion |
0.159x | -- |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more